The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

BAY 2927088, an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, led to promising response rates when used for the treatment of patients with pretreated HER2 ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on ...

The FDA approved amivantamab-vmjw (Rybrevant) plus carboplatin and pemetrexed for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon ...

Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment ...